elayeD ischemic neurological deficits due to cerebral vasospasm remain a major cause of death and morbidity after SAH despite modern treatments for ruptured cerebral aneurysms. The pathogenesis of cerebral vasospasm after SAH is not completely understood, but intracellular Ca ++ appears to be essential in the genesis of vascular constriction. Magnesium ion is a Ca ++ channel blocker and vasodilator. We have reported on the novel vasodilatory effect of the intracisternal injection of MgSO 4 solution on spastic cerebral arteries in a canine SAH model.
D
elayeD ischemic neurological deficits due to cerebral vasospasm remain a major cause of death and morbidity after SAH despite modern treatments for ruptured cerebral aneurysms. The pathogenesis of cerebral vasospasm after SAH is not completely understood, but intracellular Ca ++ appears to be essential in the genesis of vascular constriction. Magnesium ion is a Ca ++ channel blocker and vasodilator. We have reported on the novel vasodilatory effect of the intracisternal injection of MgSO 4 solution on spastic cerebral arteries in a canine SAH model. 6 Cerebral angiography 1.5 hours after the intracisternal injection of 0.5 ml/kg of 15 mmol/L MgSO 4 solution demonstrated significantly increased arterial diameters of spastic cerebral arteries; however, the optimal CSF Mg ++ concentration needed to cause vasodilation of the spastic arteries and the duration of the effect after intracisternal injection of MgSO 4 solution were not examined.
Optimal cerebrospinal fluid magnesium ion concentration for vasodilatory effect and duration after intracisternal injection of magnesium sulfate solution in a canine subarachnoid hemorrhage model
In the present study we followed the changes in the diameters of spastic cerebral arteries by using canine SAH models to elucidate the optimal CSF Mg ++ concentration for and the temporal profile of this vasodilatory effect after intracisternal injection of different concentrations of MgSO 4 solution.
Methods
All animal experiments were performed in accordance with the Institutional Guidelines and Rules of Animal Experimentation and the Guidelines for the Care and Use of Laboratory Animals of Juntendo University, Shizuoka Hospital. Cerebral vasospasm was induced using a 2-hemorrhage model in 26 female beagle dogs weighing 9-11 kg and anesthetized with an intravenous bolus injection of 20 mg/kg of pentobarbital. Anesthesia was maintained by continuous intravenous injection of 1 ml/kg/hr of propofol until the end of the procedure. The dogs were intubated using a 6 Fr endotracheal tube, and respiration was controlled with an MR imaging-compatible mobile respirator (paraPAC 2000 MR imaging, Smiths Medical). A 4 Fr, double-lumen sheath catheter was placed in the femoral artery for cerebral angiography, blood pressure monitoring, and arterial gas sampling. End-tidal CO 2 was carefully monitored, and the PaCO 2 was maintained between 35 and 45 mm Hg.
Both T1-and T2-weighted MR imaging were performed using a 1.5-T Gyroscan (Philips Medical Systems). The Evans index ([maximum bifrontal horn distance/ maximum inner diameter of skull] × 100, expressed in %) was calculated. After MR imaging, the left VA was cannulated using a 4 Fr catheter under fluoroscopic control, and digital subtraction angiography was performed after injecting 2.5 ml of iopamidol (Bayer) via an automatic injector (1.2 ml/second). After control baseline images of the VA, BA, and SCA were obtained, the cisterna magna was punctured with a 20-gauge needle, 0.3 ml/kg of CSF was removed by gravity flow, and 0.5 ml/kg of autologous arterial blood was injected into the cerebellomedullary cistern (first SAH). The Mg ++ and Ca ++ concentrations in the CSF and serum were measured via ion-selective electrodes (StatProfile CCX, NOVA Biomedical). After the blood injection, the dog's head was tilted downward at 30° for 15 minutes. The animals were then allowed to recover from anesthesia.
The second SAH was induced on Day 3 using the same procedure. On Day 7 the dogs were anesthetized and a tracheal cannula was inserted. A 4 Fr double-lumen sheath was also placed in the femoral artery. Again, T1-and T2-weighted MR imaging were performed to assess any pathological changes including ischemic ones. At 1.5 hours after inducing anesthesia, left VA angiography was performed to assess any changes in the VA, BA, and SCA following experimental SAH. Immediately after angiography, the cisterna magna was punctured with a 20-gauge needle to remove 0.3 ml/kg of CSF and to inject 0.5 ml/kg of 15 (8 animals), 10 (6 animals), 5 (6 animals), or 0 mmol/L (6 animals) MgSO Arterial diameters were measured using digital subtraction angiography (Infinix Celeve-i, Toshiba Medical Systems) with a matrix of 1024 × 1024 and automatically calibrated for conversion between millimeters and pixels to measure the arterial vessel diameter. Angiograms were recorded in real time, and the images were captured at peak arterial contrast opacification. A radiological technician unaware of the details of the experimental protocol measured the arterial diameters of the bilateral VAs at the junction with the BA. The mean of the 2 measured diameters was taken as the diameter of the VA. The arterial diameters of the BA were measured at 3 equidistant points between the junctions with the VA and the SCA. The mean of the 3 measured diameters was taken as the arterial diameter of the BA. The arterial diameters of the bilateral SCAs were measured at both sides of the junction with the BA. The mean of the 2 measured diameters was taken as the diameter of the SCA.
Data are presented as the means ± SDs. The statistical significance of differences was analyzed with 1-way ANOVA, the paired t-test, the Wilcoxon signed-rank test, linear regression, and the chi-square test by using SPSS 7.5.1 J for Windows (SPSS Japan, Inc.). A p value < 0.05 was considered statistically significant. Table 1 lists the physiological parameters and serum concentrations of Mg ++ and Ca ++ on Day 1 and before and after the intracisternal injection of the MgSO 4 solution on Day 7. The mean arterial blood pressure, hemoglobin concentration, hematocrit, arterial blood gas parameters, and serum Mg ++ and Ca ++ concentrations did not change throughout the experimental procedures. Body temperature was significantly increased on Day 7 as compared with that on Day 1 (p < 0.001) but did not show significant changes before and after the intracisternal injection of the MgSO 4 solution. The animals showed hydrocephalus on Day 7. The Evans indexes before (26.2 ± 2.2%) and after (26.2 ± 1.9%) intracisternal injection of the MgSO 4 solution on Day 7 were significantly increased as compared with that on Day 1 (19.7 ± 1.5%), but were not significantly different from one another. No other pathological changes, including ischemia, were noted on MR imaging (data not shown). Photomicrographs of the coronal sections of the BAs stained with H & E and elastica van Gieson showed SAH mainly in the ventral surface of the brainstem. The adventitia of the BA demonstrated edematous change with inflammatory cell infiltration. The internal elastic lamina showed folding and corrugation. These histological findings are typical of cerebral vasospasm (data not shown).
Results

Physiological Parameters and Morphological Changes
Correlation Between Change in Arterial Diameter and CSF Mg ++ Concentration
To examine the effects of the CSF Mg ++ concentration on arterial diameter, the ratios of the arterial diameter after intracisternal injection of the MgSO 4 solution to the diameter before injection (arterial diameter ratio) on Day 7 were plotted against the CSF Mg ++ concentration at 1, 3, and 6 hours after MgSO 4 injection. The arterial diameter ratios of the BA were positively correlated with the CSF Mg ++ concentration at 1 (R = 0.653, p < 0.001) and 3 hours (R = 0.555, p < 0.01) after injecting the MgSO 4 solution, but not at 6 hours (R = 0.258, p = 0.204) after injection (Fig.  1) . The arterial diameter ratios of the SCA were positively correlated with the CSF Mg ++ concentration at 1 hour (R = 0.608, p < 0.01) and 3 hours (R = 0.586, p < 0.01) after, but not at 6 hours (R = 0.272, p = 0.179) after intracisternal injection (Fig. 2) . The arterial diameter ratios of the VA were positively correlated with the CSF Mg ++ concentration at 1 hour after (R = 0.554, p < 0.01), but not at 3 hours (R = 0.204, p = 0.318) and 6 hours (R = 0.108, p = 0.600) after the MgSO 4 solution (Fig. 3) . The arterial diameter ratios, except 1 point in the SCA, exceeded 1 in all animals with CSF Mg ++ concentrations > 3 mEq/L at 1 hour after the intracisternal injection of MgSO 4 solution. To determine the effective concentration of Mg ++ , a chi-square test was performed with 2 categorized Mg ++ concentrations, more or less than 3 mEq/L, and 2 categorized vasodilator ratios of the artery, more or less than 1.0. Given that the statistical p values of the chi-square tests for the BA, SCA, and VA were 0.024, 0.024, and 0.046, respectively, the 3 mEq/L level caused a significant vasodilatory effect. ++ concentration returned to the baseline value at 6 hours after MgSO 4 injection (1.54 ± 0.21 mEq/L). The Ca ++ concentration before injection on Day 7 (2.24 ± 0.12 mEq/L) was slightly but significantly increased (p < 0.01), as compared with that on Day 1 (2.11 ± 0.11 mEq/L). The Ca ++ concentration was 2.34 ± 0.07 mEq/L (p < 0.01) at 1 hour, 2.37 ± 0.12 mEq/L (p < 0.01) at 3 hours, and 2.34 ± 0.14 mEq/L (p < 0.05) at 6 hours after the injection on Day 7, a significant increase as compared with the value before MgSO 4 injection. Figure 4 lower shows the temporal changes in the cerebral arterial diameters on Day 1 and before and 1, 3, and 6 hours after intracisternal injection of MgSO 4 on Day 7. The diameters of the BA, SCA, and VA before SAH on Day 1 were 1.21 ± 0.12, 0.88 ± 0.19, and 1.02 ± 0.25 mm, respectively. The BA, SCA, and VA showed significant decreases (p < 0.01) in diameter to 0.66 ± 0.13, 0.41 ± 0.07, and 0.54 ± 0.18 mm, respectively, before the injection of MgSO 4 on Day 7 as compared with their values on Day 1. The arterial diameter of the BA was significantly increased to 0.79 ± 0.16 mm (p < 0.01) at 1 hour and 0.77 ± 0.14 mm (p < 0.05) at 3 hours after injection, as compared with before injection. The arterial diameter of the SCA was significantly increased to 0.53 ± 0.09 mm (p < 0.01) at 1 hour, 0.56 ± 0.11 mm (p < 0.01) at 3 hours, and 0.49 ± 0.09 mm (p < 0.05) at 6 hours after injection, as compared with before injection. The arterial diameter of the VA was significantly increased to 0.70 ± 0.21 mm (p < 0.01) at 1 hour, 0.65 ± 0.19 mm (p < 0.05) at 3 hours, and 0.62 ± 0.16 mm (p < 0.05) at 6 hours after injection, as compared with before injection. Figure 5 lower shows the temporal changes in the cerebral arterial diameters on Day 1 and before and 1, 3, and 6 hours after intracisternal injection of the MgSO 4 or Ringer solution on Day 7. The diameters of the BA, SCA, and VA before SAH on Day 1 were 1.26 ± 0.14, 0.77 ± 0.14, and 1.08 ± 0.16 mm, respectively. The BA, SCA, and VA showed significant decreases (p < 0.01) in diameter to 0.70 ± 0.16, 0.48 ± 0.14, and 0.65 ± 0.17 mm, respectively, before the intracisternal injection of MgSO 4 or Ringer solution on Day 7, as compared with Day 1 diameters. The arterial diameter of the BA was significantly decreased at 0.63 ± 0.13 mm (p < 0.01) at 6 hours after injection, compared with before injection. The arterial diameter of the VA was significantly decreased at 0.58 ± 0.14 mm (p < 0.05) at 3 hours and 0.58 ± 0.17 mm (p < 0.05) at 6 hours after injection, compared with before injection. The ++ concentrations at 1 and 3 hours after injection were significantly increased as compared with those before injection and returned to the baseline value at 6 hours. The CSF Ca ++ concentrations at 1, 3, and 6 hours after injection were significantly increased, as compared with before injection. The diameters of the BA, SCA, and VA on Day 7 before injection were significantly decreased, as compared with those on Day 1. The arterial diameters of the BA at 1 and 3 hours after injection were significantly increased, compared with before injection. The arterial diameters of the SCA and VA at 1, 3, and 6 hours after injection were significantly increased, as compared with before injection.
Temporal Profile of the Effects of the Intracisternal
arterial diameter of the SCA did not change significantly after the MgSO 4 injection.
Representative angiograms illustrating the development of vasospasm on Day 7 and the reversal effects at 1-6 hours after the intracisternal injection of the MgSO 4 solution (15 mmol/L) are presented in Fig. 6 .
Discussion
Data in a previous study demonstrated the vasodilatory effect of the intracisternal injection of MgSO 4 solution on spastic cerebral arteries in a canine SAH model utilizing angiography.
6 Using a quantitative autoradiographic technique, we have also shown that the intracisternal infusion of MgSO 4 solution improves reduced cerebral blood flow after experimental SAH in the rat. 7 Note, however, that the optimal CSF concentration of Mg ++ to dilate spastic cerebral arteries and the duration of its vasodilatory effect were not investigated.
Data in the present study showed that the arterial diameter ratios of the BA and SCA at 1 and 3 hours and of the VA at 1 hour after the intracisternal injection of MgSO 4 solution were significantly correlated with the CSF Mg ++ concentration. We also demonstrated that animals with a CSF Mg ++ concentration > 3 mEq/L at 1 hour after intracisternal injection of the MgSO 4 solution had increased diameters of spastic cerebral arteries. The present findings suggest that the CSF Mg ++ concentration should be increased to > 3 mEq/L to dilate spastic cerebral arteries after SAH. Despite a decline in the CSF Mg ++ concentration to below 3 mEq/L at 3 hours after and a return to baseline at 6 hours after intracisternal injection of the MgSO 4 solution, the diameter of spastic arteries continued to be significantly dilated for 3-6 hours. Our results suggest that continuous intracisternal infusion or intermittent injection of MgSO 4 solution would be necessary to maintain the optimal CSF Mg ++ concentration and constantly ameliorate cerebral vasospasm.
Results in the present study also indicated a slight but significantly increased CSF Ca ++ concentration at 1-6 hours after intracisternal injection of MgSO 4 solution in the animals with dilated spastic cerebral arteries. The increased CSF Ca ++ concentration may result from the inhibition of extracellular Ca ++ influx due to the Ca ++ blocker effect of the increased extracellular Mg ++ concentration. Therefore, the mechanism of the vasodilatory effect of the intracisternal injection of MgSO 4 solution on spastic cerebral arteries following SAH might be mediated by the Ca ++ channel blocker effect of the increased extracellular Mg ++ concentration. Several clinical trials have reported that the intravenous infusion of MgSO 4 reduces the occurrence of delayed neurological ischemia and improves outcome after aneurysmal SAH, presumably mediated by the neuroprotective effects of Mg such as the inhibition of excitatory amino acid (glutamate) and the blockage of voltage-dependent calcium channels and N-methyl-D-aspartic acid receptors. 3, 9, [15] [16] [17] [18] [19] [20] But 2 prospective randomized controlled trials on the continuous intravenous administration of MgSO 4 in patients with SAH failed to show any vasodilatory effect on vasospastic vessels according to angiography and transcranial Doppler ultrasonography.
10,12
Continuous intravenous infusion of MgSO 4 also failed to reverse spastic cerebral arteries in an in vivo SAH model in monkeys. 4 The absence of expected vasodilatory effects on the spastic cerebral arteries after the intravenous infusion of MgSO 4 , despite the increased blood concentration of Mg ++ , is considered to result from the relative impermeability of the blood-brain barrier to Mg ++ in the blood. Extracellular Mg ++ concentration is key to the regulation of vascular smooth muscle tone.
2,14 An increased extracellular Mg ++ concentration definitely causes vasodilation of both normal and contracted cerebral arteries in the presence of vasospasm-inducing agents in vitro.
1,5
Cerebrospinal fluid Mg ++ concentrations in the range of 2.4-9.6 mEq/L have caused the dilation of normal arterioles in the cat.
11 Therefore, the intravenous infusion of MgSO 4 cannot increase the extracellular Mg ++ concentration in the brain to a level adequate to dilate spastic cerebral arteries. ++ concentration at 1 hour after injection was significantly increased compared with before injection and returned to the baseline value at 3 and 6 hours after. The CSF Ca ++ concentrations after injection were not significantly increased compared with before injection. The diameters of the BA, SCA, and VA on Day 7 before injection were significantly decreased compared with those of Day 1. The arterial diameter of the BA at 6 hours was significantly decreased compared with before injection. The arterial diameters of the VA at 3 and 6 hours after injection were significantly decreased compared with before injection.
Data in the present study also revealed that animals with CSF Mg ++ concentrations < 3 mEq/L at 1 hour after the intracisternal injection of MgSO 4 or Ringer solution demonstrated further decreases in the diameters of the spastic cerebral arteries of the VA and BA. The decreased arterial diameters were observed mainly in the animals treated with the intracisternal injection of Ringer solution without MgSO 4 (Figs. 1-3 ). This finding suggests that cisternal irrigation therapy without Mg ++ may worsen cerebral vasospasm in patients with SAH.
Several clinical studies on the intracisternal infusion of MgSO 4 therapy in patients with aneurysmal SAH have shown a reduction in the incidence of symptomatic vasospasm and the reversible effect on angiographic vasospasm. 8, 13 Data in the present study demonstrated that the injection of an intracisternal MgSO 4 solution had a positive but moderate vasodilatory effect. Therefore, this therapy may require combination with some other adjunct treatment, such as hemolytic irrigation to wash out the subarachnoid blood clot. A preliminary clinical study of the intracisternal infusion of MgSO 4 solution has documented some unfavorable effects, such as anesthesia and respiratory suppression in patients who required admission to the intensive care unit. 8 Based on the results of our experimental studies, a randomized controlled clinical study of intracisternal infusion therapy in patients with aneurysmal SAH is currently underway at our institution.
Conclusions
The reversible effect of the intracisternal injection of MgSO 4 solution on the spastic artery required CSF Mg ++ concentrations > 3 mEq/L. The vasodilatory effect continued for 3-6 hours after the intracisternal MgSO 4 injection. These results suggest that the continuous infusion or intermittent intracisternal injection of MgSO 4 is needed to maintain the optimal CSF Mg ++ concentration and constantly ameliorate cerebral vasospasm. 
